DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for familial partial lipodystrophy — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFamilial partial lipodystrophy maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for familial partial lipodystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
peroxisome proliferator activated receptor gamma (PPARG) — PPARG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 9cisdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3DZY · 3.1 Å · ligand (9cis)-retinoic acid (9CR). Experimental structure, not a prediction.
What the evidence adds up to
A mother and daughter with a novel type of familial partial lipodystrophy showed atrophy of fat in the face, chest, and upper and lower limbs, with abdominal obesity from intraabdominal fat accumulation. The mother had severe insulin resistance and impaired glucose tolerance; the daughter had normal glucose tolerance and normal insulin sensitivity. Both had metabolic rates about 30% above normal levels, with normal thyroid function and plasma lipids. This 1995 report involved only two patients.
A 2025 review states there is currently no definitive cure for lipodystrophy syndromes, which include familial partial lipodystrophy. Clinical management remains symptomatic. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies target specific complications. Novel interventions are under investigation to address unmet clinical needs, but no cure exists.
A 2025 case report describes a patient with familial partial lipodystrophy syndrome type 6 due to a heterozygous LIPE gene defect, which is very rare. The heterozygous nature produced a milder clinical form. Genetic testing was required to confirm the diagnosis. The report does not provide any treatment outcome data.
What is still missing are large, controlled trials for any drug in familial partial lipodystrophy specifically, funding for such trials given the rarity of the condition, and reliable patient stratification by genotype to test targeted therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 1995 · 11 citations
An unusual type of familial lipodystrophy.
AbstractA mother and her daughter with a novel type of familial partial lipodystrophy were studied. Both had atrophy of fat in the face, chest, and upper and lower limbs and abdominal obesity caused by intraabdominal fat accumulation. The mother had severe insulin resistance and impaired glucose tolerance, whereas the daughter had normal glucose tolerance and normal insulin sensitivity. Both had metabolic rates about 30% above normal levels, but normal thyroid function and plasma lipids.
Expert Review of Endocrinology & Metabolism · 2025 · 2 citations · open access
Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions
AbstractINTRODUCTION: Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue, which may be either inherited or acquired. Loss of adipose tissue in typical storage sites starting from birth or later in life, combined with abnormal fat accumulation in other organs, contributes to multiple metabolic complications. There is currently no definitive cure available for lipodystrophy syndromes, and clinical management remains symptomatic. AREAS COVERED: For this review, available databases were searched to identify publications and studies on current and emerging therapies to discuss the management of lipodystrophy syndromes. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies are used to target specific complications. Novel interventions are under investigation to address unmet clinical needs. EXPERT OPINION: There is currently no cure for lipodystrophy syndromes. Emerging therapies are being investigated to expand therapeutic options and improve long-term outcomes of this complex disorder.
Journal of the Association of Physicians of India · 2025 · 1 citations
Interesting Case of Familial Partial Lipodystrophy Syndrome (Type 6) with LIPE Gene Defect: A Case Report
AbstractWe report on an interesting case of familial partial lipodystrophy syndrome (type 6) due to a LIPE gene defect. Lipodystrophy syndromes are characterized by dysfunctional adipose tissue. While there are several types of lipodystrophies, this report is of a case of familial partial lipodystrophy with a LIPE gene mutation, which is very rare. Because the LIPE gene defect was of heterozygous nature, it presented in a milder clinical form. Thanks to genetic testing, we were able to clinch the diagnosis in this case. This case teaches us that we should have a high index of suspicion to pick up such rare cases and to offer genetic testing whenever indicated.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
